Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 12/20 | 0.32 |
| ▸ | CDK8 | P49336 | 12/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3119994 | 0.97 | OTUD7B (0.46) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| SCHEMBL324340 | 0.97 | OTUD7B (0.46) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| Hydrochloric Acid SCHEMBL325043 | 0.95 | OTUD7B (0.44) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| Hydrochloric Acid SCHEMBL30159811 | 0.95 | OTUD7B (0.44) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| Hydrochloric Acid SCHEMBL2637274 | 0.89 | CRBN (0.38) | OTUD7BCRBNNEK2HSD17B10 | |
| SCHEMBL21238918 | 0.89 | OTUD7B (0.41) | OTUD7BCRBNNEK2HSD17B10CCNC | |
| SCHEMBL479513 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL19032354 | 0.86 | CRBN (0.59) | OTUD7BCRBN | |
| SCHEMBL2023430 | 0.86 | CRBN (0.39) | OTUD7BCRBNNEK2HSD17B10 | |
| SCHEMBL23009666 | 0.84 | CRBN (0.38) | OTUD7BCRBNNEK2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | disclosed |
| EP-2569318-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141729-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116270-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | OTUD7B 3372/4885CRBN 3202/4885NEK2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.